How Hormonal Therapy Works Against Breast and Prostate Cancer

Some tumors grow because of a mistake in their DNA that revs up cell division on its own. Others behave more like a plant chasing sunlight: they keep growing only as long as a particular signal keeps arriving. Many breast cancers and most prostate cancers fall into this second category. They depend on hormones, the body's own chemical messengers, to keep dividing. Hormonal therapy works by cutting off that signal, rather than attacking the cancer cell directly the way chemotherapy does.

Two Hormones, Two Different Cancers

Breast cancer cells that depend on hormones usually carry a protein called the estrogen receptor. When estrogen attaches to this receptor, it acts like a key turning a lock, switching on genes that tell the cell to grow. Prostate cancer cells rely on a related but distinct protein, the androgen receptor, which responds to testosterone and other androgens in much the same way. The lock-and-key idea is similar in both cancers, but the hormones involved are different, and so are the drugs built to interrupt them.

Doctors test tumors for these receptors because their presence is what makes hormonal therapy a reasonable option in the first place. Cancers that lack the estrogen receptor or androgen receptor generally do not respond to hormone-blocking drugs, since they are not actually plugged into that signal.

Blocking the Receptor Itself: Tamoxifen

One of the earliest drugs built specifically to interrupt a hormone receptor was tamoxifen. It works as a selective estrogen receptor modulator, a class of drug often shortened to SERM. Rather than lowering estrogen levels in the body, tamoxifen goes straight to the estrogen receptor and physically occupies it, competing with estrogen for the same spot the way an understudy might take the lead role, leaving the intended performer with nowhere to stand.

In breast tissue, tamoxifen locks onto the receptor and holds it in a shape that does not switch on the growth genes. The twist is that tamoxifen behaves differently depending on the tissue. In other tissues, such as the uterus, it can activate the receptor instead of blocking it. This tissue-selective behavior is part of what makes tamoxifen both useful and complicated, and it is a major reason the drug's development is often described as a pioneering moment in cancer medicine, work closely associated with researcher V. Craig Jordan.

What the Trials Actually Showed

Describing tamoxifen as useful is one thing; proving it saves lives required decades of large trials. A patient-level analysis pooling data from thousands of women across many randomized trials found that several years of adjuvant tamoxifen, meaning tamoxifen given after initial treatment to prevent the cancer from returning, meaningfully reduced both the chance of recurrence and the chance of dying from estrogen receptor-positive breast cancer. The benefit was specific to tumors that actually carried the estrogen receptor, which fits the underlying biology: tamoxifen has little reason to help a tumor that never relied on estrogen signaling to begin with.

Cutting Off the Hormone Supply

Breast and prostate cancer also respond to a second strategy. Instead of blocking the receptor, lower the amount of hormone circulating in the body in the first place. In breast cancer, aromatase inhibitors block an enzyme the body needs to manufacture estrogen, starving estrogen receptor-positive tumors of their fuel. In prostate cancer, androgen deprivation therapy achieves something similar by interfering with the hormonal signals that normally tell the testicles to produce testosterone. Both approaches share the same basic logic as removing a plant's water supply rather than cutting its leaves: the receptor is still there, but the signal it depends on stops arriving.

When Prostate Cancer Stops Responding

Androgen deprivation therapy often controls prostate cancer for years, but it is rarely permanent. Many tumors eventually find ways to keep the androgen receptor switched on even when testosterone levels in the blood are very low, a transition that marks the shift to castration-resistant prostate cancer. A large genomic study of advanced, treatment-resistant tumors found that these cancers frequently alter the androgen receptor gene itself, sometimes amplifying it, sometimes mutating it, in ways that let the receptor keep signaling with little or no hormone present. In effect, the lock changes shape just enough to turn without the original key.

Newer Drugs That Close the Loophole

This discovery helped justify a newer generation of hormonal drugs designed to block androgen receptor activity more thoroughly, or to cut off androgen production from sources beyond the testicles. Abiraterone works this way, blocking an enzyme needed to produce androgens throughout the body, not only in the testicles. In a large randomized trial of men with metastatic castration-resistant prostate cancer, abiraterone improved overall survival compared with standard care. Enzalutamide, a related drug that binds the androgen receptor more tightly than older anti-androgens, follows a similar principle of shutting down receptor signaling more completely, though it is best understood as part of the same broader strategy rather than interchangeable in every clinical situation.

Breast Cancer's Own Route Around Treatment

Estrogen receptor-positive breast cancer can develop resistance through a different route. In some tumors that stop responding to hormonal therapy after months or years, the gene that encodes the estrogen receptor, called ESR1, acquires mutations in the region of the protein that normally binds estrogen. These mutations can lock the receptor into an active shape even without estrogen attached, so the growth signal stays on regardless of how little estrogen is available. This finding helps explain why some tumors keep growing even after aromatase inhibitors have driven estrogen levels very low, since the tumor no longer needs estrogen to keep the receptor switched on.

Benefits, Limits, and the Decisions They Involve

None of this makes hormonal therapy a cure. It is better understood as a long-term control strategy for cancers that depend on a specific hormonal signal, one that can keep disease in check for years without eliminating every cell capable of adapting. Hormonal therapies also carry real side effects, ranging from menopause-like symptoms and bone density loss to effects on mood and cardiovascular risk, and these trade-offs differ by drug, dose, and duration. Decisions about which hormonal therapy to use, for how long, and in what combination are specific to each patient's tumor biology and overall health, and they belong with an oncologist who can weigh the evidence against an individual's circumstances.

Understanding why these drugs work, and why resistance eventually develops, does not change those individual decisions. But it does explain why a treatment that interrupts a hormone signal, rather than attacking cancer cells directly, can control disease for years, and why researchers keep watching for the molecular workarounds tumors eventually find.